With over 25 years‘ experience, HOF Sonderanlagenbau GmbH is the leading specialist in the manufacture of individual freeze drying systems, loading and unloading systems, as well as freeze-thaw units for the pharmaceutical and biotechnological industry. At our company location in Lohra, near Marburg, Germany, highly motivated and specially qualified employees work on the company‘s own production floor of some 12,500m2. A flexible service team keeps close contact with our customers, both nationally and internationally, providing support for the users of HOF systems.


In the pharmaceutical and biotechnological environment, quality and reliability are the decisive parameters in determining whether a company will be successful or not. This is guaranteed by using HOF‘s customized systems, but also because the company‘s systems technology is developed with an eye on the requirements of the future. The company, a specialist in individual solutions since its founding, distinguishes itself by offering only the highest quality in all stages: from the idea to the fully developed plan, all the way to the scrupulous manufacture of the system, which is customized and convincingly reliable. HOF systems are always a good investment for the future.


You are welcome to watch our Corporate Video on our homepage.

TECHNOLOGY

At HOF, it isn‘t technology which determines the product - it‘s the product properties which determine the technology. We rely on the most modern technological advances in our facilities and systems so we can provide our customers with excellent results, as reliably and as efficiently as possible. These technological advances include, for example, recipe-controlled automatic shelf adjustment, the use of PAT sensor technology, comparative pressure measurement and our controlled nucleation method ‘SYNCHROFREEZE’.

INNOVATION

Future-proof, high-performance and practice-oriented – these are the decisive parameters by which HOF systems measure themselves. The company is well-known for creative products which are developed to satisfy customer requirements using the latest technologies. Innovative solutions and individual designs help our customers to successfully achieve their goals.

CONSULTING

A team of experienced employees will give you individual advice from the very beginning of a project and accompany you as a partner through all processes up to the point when the system is working successfully. You can rely on employees who were trained especially for this task by HOF.

MANUFACTURE

Our dominant position compels us to be consistently excellent in our performance, high quality and farsightedness when developing trendsetting technologies. All HOF systems are manufactured and inspected fully by our employees at our production sites. This way we are able to guarantee the highest standards of quality. 

QUALITY

With every HOF system, our goal is only achieved when the result fully meets your expectations, not to 99%, but to the full 100%. For HOF, quality is the highest measure of things, and that applies to all areas, from the concept all the way to service – you can count on that!

EXPERTISE

The knowledge, ability and experience of our employees form the basis of our work. Decisive investments in our future are comprehensive training and a continual transfer of knowledge, which ensures that our highly qualified employees have wide-ranging expertise and can identify themselves with the products of HOF. This large set of skills gives you the security of knowing you‘ve made the right choice, which you can rely on during everyday production. 

Go to article: Home | Trust In Big PharmaGo to article: EditorialGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: FreudenbergGo to article: The Pharma Industry BriefingGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: Humira: the highs and lows of the world’s most successful drug Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Gene therapy: talking smart solutions with Bluebird BioGo to article: Moehs Iberica Company InsightGo to article: Moehs Iberica SLGo to article: A research headache: improving the understanding of chronic migraine Go to article: SensitechGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Philanthropy in pharma: a look inside the ISPE FoundationGo to article: DelSiTechGo to article: Novel Oral Therapies Are An Unmet Need For Ulcerative ColitisGo to article: PhoenixGo to article: FDA removes key barrier to US biosimilar developmentGo to article: Nipro PharmaPackagingGo to article: Pfizer price hikes: do rare cancer drugs warrant higher prices?Go to article: AlpexGo to article: Head-to-head: competing for the most effective psoriasis drugGo to article: Mecmesin Company InsightGo to article: MecmesinGo to article: Takeda to seek label expansion for Ninlaro in multiple myelomaGo to article: Capsugel Company InsightGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s EpidiolexGo to article: EcocoolGo to article: Abiogen PharmaGo to article: Illegal online pharmacies: how endemic are they?Go to article: Global Freight Solutions LtdGo to article: The boom in medical cannabis research is set to continueGo to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Population boom will boost acute stroke market, particularly in ChinaGo to article: Pall BiotechGo to article: Cryo StoreGo to article: Watch Alibaba instead of Amazon in healthcareGo to article: WIKA - Disaster preventionGo to article: AstraZeneca’s Lynparza maintains lead in PARP inhibitor raceGo to article: G.F.Go to article: Erdmann Design SwitzerlandGo to article: CMV presents a serious concern in HIV+ personsGo to article: BEA TechnologiesGo to article: BaxterGo to article: bDMARD therapy: adherence in the first year is key to successGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: End the struggle: pathways to HEAL the opioid crisisGo to article: LaudaGo to article: AbbVie poised to overtake Gilead as hepatitis C leaderGo to article: ILC Dover IncGo to article: ViiV results show the importance of INIs to future HIV treatmentGo to article: PfanstiehlGo to article: Novartis acquires rights to atopic dermatitis candidate MOR106Go to article: Niconex Medical LtdGo to article: EventsGo to article: Next issue